Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies

BACKGROUND: Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days in phase 2 and 3 trials. In these analyses, we aimed to evaluate the safety and tolerability of galcanezumab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Neurol
Autors principals: Bangs, Mark E., Kudrow, David, Wang, Shufang, Oakes, Tina M., Terwindt, Gisela M., Magis, Delphine, Yunes-Medina, Laura, Stauffer, Virginia L.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6966798/
https://ncbi.nlm.nih.gov/pubmed/31952501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-020-1609-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars